Patents by Inventor Bill J. Smith

Bill J. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METABOLITES OF BICTEGRAVIR
    Publication number: 20220249499
    Abstract: The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir.
    Type: Application
    Filed: January 11, 2022
    Publication date: August 11, 2022
    Inventors: Haolun Jin, Hyung-Jung Pyun, Bill J. Smith, Raju Subramanian, Jianhong Wang
  • Metabolites of bictegravir
    Patent number: 11253524
    Abstract: The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 22, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Haolun Jin, Hyung-Jung Pyun, Bill J. Smith, Raju Subramanian, Jianhong Wang
  • METABOLITES OF BICTEGRAVIR
    Publication number: 20190224206
    Abstract: The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Haolun Jin, Hyung-Jung Pyun, Bill J. Smith, Raju Subramanian, Jianhong Wang
  • Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists
    Patent number: 6564152
    Abstract: The present invention relates to novel screening methods which enable the selection of neurokinin-1 (NK-1) receptor antagonist compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes, in particular, CYP2D6. The present invention also relates to a method of generating a pharmacophore model for the CYP2D6 inhibitory activity of NK-1 receptor antagonist compounds; to methods for the discovery of molecules that are potential NK-1 receptor antagonist compounds which do not possess significant inhibitory potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting NK-1 receptor antagonist molecules which do not possess significant potency towards CYP2D6.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: May 13, 2003
    Assignee: Pfizer Inc
    Inventors: Sean Ekins, Bill J. Smith
  • Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists
    Publication number: 20020052693
    Abstract: The present invention relates to novel screening methods which enable the selection of neurokinin-1 (NK-1) receptor antagonist compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes, in particular, CYP2D6. The present invention also relates to a method of generating a pharmacophore model for the CYP2D6 inhibitory activity of NK-1 receptor antagonist compounds; to methods for the discovery of molecules that are potential NK-1 receptor antagonist compounds which do not possess significant inhibitory potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting NK-1 receptor antagonist molecules which do not possess significant potency towards CYP2D6.
    Type: Application
    Filed: January 17, 2001
    Publication date: May 2, 2002
    Inventors: Sean Ekins, Bill J. Smith